全文获取类型
收费全文 | 81315篇 |
免费 | 6367篇 |
国内免费 | 232篇 |
专业分类
耳鼻咽喉 | 1026篇 |
儿科学 | 1930篇 |
妇产科学 | 1230篇 |
基础医学 | 10295篇 |
口腔科学 | 1293篇 |
临床医学 | 9158篇 |
内科学 | 17146篇 |
皮肤病学 | 984篇 |
神经病学 | 7755篇 |
特种医学 | 2890篇 |
外国民族医学 | 8篇 |
外科学 | 13793篇 |
综合类 | 1085篇 |
一般理论 | 56篇 |
预防医学 | 6277篇 |
眼科学 | 1813篇 |
药学 | 5864篇 |
中国医学 | 84篇 |
肿瘤学 | 5227篇 |
出版年
2023年 | 530篇 |
2022年 | 829篇 |
2021年 | 2300篇 |
2020年 | 1401篇 |
2019年 | 2077篇 |
2018年 | 2489篇 |
2017年 | 1721篇 |
2016年 | 1900篇 |
2015年 | 2158篇 |
2014年 | 3092篇 |
2013年 | 3921篇 |
2012年 | 6014篇 |
2011年 | 6280篇 |
2010年 | 3381篇 |
2009年 | 3080篇 |
2008年 | 5087篇 |
2007年 | 5265篇 |
2006年 | 5079篇 |
2005年 | 4804篇 |
2004年 | 4371篇 |
2003年 | 4138篇 |
2002年 | 3718篇 |
2001年 | 984篇 |
2000年 | 913篇 |
1999年 | 908篇 |
1998年 | 824篇 |
1997年 | 666篇 |
1996年 | 561篇 |
1995年 | 509篇 |
1994年 | 447篇 |
1993年 | 414篇 |
1992年 | 607篇 |
1991年 | 572篇 |
1990年 | 509篇 |
1989年 | 507篇 |
1988年 | 458篇 |
1987年 | 424篇 |
1986年 | 418篇 |
1985年 | 393篇 |
1984年 | 380篇 |
1983年 | 320篇 |
1982年 | 258篇 |
1981年 | 217篇 |
1980年 | 215篇 |
1979年 | 239篇 |
1978年 | 214篇 |
1977年 | 186篇 |
1976年 | 161篇 |
1974年 | 191篇 |
1973年 | 165篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
91.
Betsy D. Kennard Susan G. Silva Simon Tonev Paul Rohde Jennifer L. Hughes Benedetto Vitiello Christopher J. Kratochvil John F. Curry Graham J. Emslie Mark Reinecke John March 《Journal of the American Academy of Child and Adolescent Psychiatry》2009,48(2):186-195
ObjectiveWe examine remission rate probabilities, recovery rates, and residual symptoms across 36 weeks in the Treatment for Adolescents with Depression Study (TADS).MethodThe TADS, a multisite clinical trial, randomized 439 adolescents with major depressive disorder to 12 weeks of treatment with fluoxetine, cognitive–behavioral therapy, their combination, or pill placebo. The pill placebo group, treated openly after week 12, was not included in the subsequent analyses. Treatment differences in remission rates and probabilities of remission over time are compared. Recovery rates in remitters at weeks 12 (acute phase remitters) and 18 (continuation phase remitters) are summarized. We also examined whether residual symptoms at the end of 12 weeks of acute treatment predicted later remission.ResultsAt week 36, the estimated remission rates for intention-to-treat cases were as follows: combination, 60%; fluoxetine, 55%; cognitive–behavioral therapy, 64%; and overall, 60%. Paired comparisons reveal that, at week 24, all active treatments converge on remission outcomes. The recovery rate at week 36 was 65% for acute phase remitters and 71% for continuation phase remitters, with no significant between-treatment differences in recovery rates. Residual symptoms at the end of acute treatment predicted failure to achieve remission at weeks 18 and 36.ConclusionsMost depressed adolescents in all three treatment modalities achieved remission at the end of 9 months of treatment. 相似文献
92.
93.
94.
95.
The incidence of AIDS among blacks and Hispanics 总被引:3,自引:0,他引:3
R Bakeman E McCray J R Lumb R E Jackson P N Whitley 《Journal of the National Medical Association》1987,79(9):921-928
Compared with whites, the acquired immune deficiency syndrome (AIDS) has affected blacks and Hispanics disproportionately. The cumulative incidence (CI) for black men was 2.6, and for Hispanic men 2.5, times the rate for white men. Intravenous (IV) needle use alone does not account for this difference. Not counting IV needle-using cases, the CIs for black and Hispanic men were 1.7 times the CI for white men. Although there were fewer cases in women than men, the white-to-minority disparity was greater for women. The CIs for black and Hispanic women were 12.2 and 8.5 times, respectively, the CI for white women. Prevention programs are urgently needed and should focus on risky behavior (IV needle sharing and receptive anal intercourse), not just risk groups. 相似文献
96.
Penny H Feldman Christopher M Murtaugh Liliana E Pezzin Margaret V McDonald Timothy R Peng 《Health services research》2005,40(3):865-886
OBJECTIVE: To assess the impact and cost-effectiveness of two information-based provider reminder interventions designed to improve self-care management and outcomes of heart failure (HF) patients. DATA SOURCES/STUDY SETTING: Interview and agency administrative data on 628 home care patients with a primary diagnosis of HF. STUDY DESIGN: Patients were treated by nurses randomly assigned to usual care or one of two intervention groups. The basic intervention was an e-mail to the patient's nurse highlighting six HF-specific clinical recommendations. The augmented intervention supplemented the initial nurse reminder with additional clinician and patient resources. DATA COLLECTION: Patient interviews were conducted 45 days post admission to measure self-management behaviors, HF-specific outcomes (Kansas City Cardiomyopathy Questionnaire-KCCQ), health-related quality of life (EuroQoL), and service use. PRINCIPAL FINDINGS: Both interventions improved the mean KCCQ summary score (15.3 and 12.9 percent, respectively) relative to usual care (p< or =.05). The basic intervention also yielded a higher EuroQoL score relative to usual care (p< or =.05). In addition, the interventions had a positive impact on medication knowledge, diet, and weight monitoring. The basic intervention was more cost-effective than the augmented intervention in improving clinical outcomes. CONCLUSIONS: This study demonstrates the positive impact of targeting evidence-based computer reminders to home health nurses to improve patient self-care behaviors, knowledge, and clinical outcomes. It also advances the field's limited understanding of the cost-effectiveness of selected strategies for translating research into practice. 相似文献
97.
98.
99.
100.
Alemtuzumab (CAMPATH 1H) Induction Therapy in Cadaveric Kidney Transplantation—Efficacy and Safety at Five Years 总被引:2,自引:0,他引:2
Christopher J. E. Watson J. Andrew Bradley Peter J. Friend John Firth Craig J. Taylor John R. Bradley Kenneth G. C. Smith Sathia Thiru Neville V. Jamieson Geoff Hale Herman Waldmann Roy Calne 《American journal of transplantation》2005,5(6):1347-1353
Alemtuzumab is a powerful lymphocyte depleting antibody currently being evaluated in solid organ transplantation. This paper describes 5-year results of a single center study of alemtuzumab as induction in renal transplantation. Thirty-three renal transplant recipients received 20 mg alemtuzumab on day 0 and 1, followed by half-dose cyclosporin monotherapy (trough concentration 75-125 ng/mL) from day 3. They were compared in a retrospective contemporaneous-controlled manner with 66 kidney transplant recipients transplanted in the same period and center who received conventional immunosuppression with cyclosporin, azathioprine and prednisolone. In the alemtuzumab group 12% of recipients died compared to 17% in the control group (p = 0.48); likewise graft loss was similar in both groups (21% vs. 26%, respectively, p = 0.58). Incidence of acute rejection was also comparable at 5 years (31.5% vs. 33.6%), although the pattern of rejection was different with 14% patients in the alemtuzumab group experiencing rejection over 1 year post-transplant compared to none in the control group. There was no significant difference between groups in terms of infection or serious adverse events. While acknowledging the limitations of a relatively small single-center study, results suggest that alemtuzumab induction allowed satisfactory long-term patient and graft survival equivalent to that seen with standard triple immunosuppression, while avoiding steroid therapy. 相似文献